NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients

British Journal of Cancer

Volumn 115, Issue 10, 2016, Pages 1264-1272

  Prochazka, Katharina T ^a   Melchardt, Thomas ^b   Posch, Florian ^a   Schlick, Konstantin ^b   Deutsch, Alexander ^a   Beham Schmid, Christine ^a   Weiss, Lukas ^b   Gary, Thomas ^a   Neureiter, Daniel ^c   Klieser, Eckhard ^c   Greil, Richard ^b   Neumeister, Peter ^a   Egle, Alexander ^b   Pichler, Martin ^a,d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Oncologic Center   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

DLBCL; prognosis; uric acid

Indexed keywords

URIC ACID; ANTINEOPLASTIC AGENT; RITUXIMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLASSIFIER; CLINICAL OUTCOME; DISEASE COURSE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; URIC ACID BLOOD LEVEL; AUSTRIA; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRIA; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RITUXIMAB; URIC ACID;

EID: 84992018150     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.325     Document Type: Article

References (28)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tra, n T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) WHO classification of tumours of hematopoietic and lymphoid tissues. Blood 117: 5019-5032.
3. Chen YF, Li Q, Chen DT, Pan JH, Chen YH, Wen ZS, Zeng WA (2016) Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy. Cancer Biomark 17: 89-96.
4. Cuhadar S, Atay1 A, Koseoglu M, Dirican A, Hur A (2012) Stability studies of common biochemical analytes in serum separator tubes with or without gel barrier subjected to various storage conditions. Biochem Med 22: 202-214.
5. Fini MA, Elias A, Johnson RJ, Wright RM (2012) Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 1: 16.
6. Hille R (2005) Molybdenum-containing hydroxylases. Arch Biochem Biophys 433: 107-116.
7. Hochberg J, Cairo MS (2008) Tumor lysis syndrome: current perspective. Haematologica 93: 9-13.
8. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS (2014) Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology 25: 114-121.
9. Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362: 1417-1429.
10. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J (1989) Serum uric acid and 11. 5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 42: 257-267.
11. Marjani A (2006) Effect of storage time and temperature on some serum analytes. Internet J Lab Med 2: 1-6.
12. Marubini E, Morabito A, Valsecchi MG (1983) Prognostic factors and risk groups: some results given by using an algorithm suitable for censored survival data. Stat Med 2: 295-303.
13. Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, Greil R, Pichler M, Egle A (2014) A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and b2-microglobulin. Br J Haematol 168: 239-245.
14. Petersson B, Trell E (1983) Raised serum urate concentration as risk factor for premature mortality in middle aged men: relation to death from cancer. Br Med J 287: 7-9.
15. Posch F, Riedl J, Reitter EM, Kaider A, Zielinski C, Pabinger I, Ay C (2016) Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model. Thromb Haemost 115: 817-826.
16. Redrup MJ, Igarashi H, Schaefgen J, Lin J, Geisler L, Ben M'Barek M, Ramachandran S, Cardoso T, Hillewaert V (2016) Sample management: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J 18: 290-293.
17. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17: 343-346.
18. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861.
19. Selcukbiricik F, Kanbay M, Solak Y, Bilici A, Kantez M, Balk E, Mandel NM (2016) Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer. Clin Transl Oncol; e-pub ahead of print 19 January 2016; doi:10. 1007/s12094-016-1485-1.
20. Shepshelovich D, Ram R, Uziel O, Kushnir M, Lithwick-Yanai G, Hoshen M, Feinmesser M, Bairey O, Lahav M (2015) MicroRNA signature is indicative of long term prognosis in diffuse large B-cell lymphoma. Leuk Res 39: 632-637.
21. Shipp MA et al. on behalf of The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive Non-Hodgkin's Lymphoma. N Engl J Med 329: 987-994.
22. Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, Gary T, Kornprat P, Schaberl-Moser R, Hoefler G, Gerger A, Pichler M (2014) Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One 18: e104730.
23. Szkandera J, Gerger A, Liegl-Atzwanger B, Stotz M, Samonigg H, Ploner F, Stojakovic T, Gary T, Leithner A, Pichler M (2014) Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients. Clin Chem Lab Med 53: 493-597.
24. Terkeltaub R (2010) Update on gout: new therapeutic strategies and options. Nat Revies Rheumatol 6: 30-38.
25. Tilly H, Vitolo U, Walewski J, da Silva MG, Shpilberg O, André M, Pfreundschuh M, Dreyling M. ESMO Guidelines Working Group (2012) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23: 78-82.
26. Troppan K, Deutsch A, Gerger A, Stojakovic T, Beham-Schmid C, Wenzl K, Neumeister P, Pichler M (2014) The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 110: 369-374.
27. Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, Hua C, Wang X, Xu D, Sun B (2015) Serum uric acid increases risk of cancer incidence and mortality: a systematic review and meta-analysis. Mediators Inflamm 2015: 764250.
28. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123: 837-842.